fda tirzepatide obesity GROUNDBREAKING UPDATE! has approved TIRZEPATIDE, a pioneering treatment activating GIP & GLP-1 receptors, for weight loss! Previously, has been FDA approved for type 2 diabetes as Mounjaro, and although F.D.A. Approves New Obesity Drug

Many women with PCOS use this combination to address both insulin resistance and weight management simultaneously

Everything flows from here

These typically present as: Localised redness (erythema) around the injection area Swelling or raised bumps that may feel warm to touch Itching or mild discomfort at the site Small nodules or lumps that can persist for several days These localised reactions usually appear within hours to days of administration and often resolve spontaneously within a few days to a week

PlexusDx recommends choosing a specific day and time, then sticking to it within a 2 hour window for best results and medication consistency

GLP-1R agonist treatment also leads to a mild decrease in cholesterol levels (total, LDL, and triglyceride), an additional factor that participates in the pathogenesis and progression of such kidney disease [76]

The injectable form of Semaglutide can be prescribed for chronic weight management for those diagnosed as clinically obese (body mass index of 30 or greater) and those categorized as overweight, as long as they have at least one weight-related health condition